Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cspc Megalith Biopharmarceutical Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner and a distinct art unit. The company's current interaction with the patent office is focused on this one specific matter. This narrow scope of activity indicates that the company's intellectual property efforts are currently concentrated on a single technical development within the biotechnology field.
SAOUD, CHRISTINE J is the busiest examiner for the portfolio, with 1 pending office action. This accounts for the total number of pending office actions currently active for the company. The involvement of a distinct examiner and a distinct art unit shows that the current workload is not distributed across multiple personnel or administrative divisions. This singular point of contact simplifies the administrative tracking of the company's patent applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAOUD, CHRISTINE J | 1 | 57.9% | +37.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18685971 | ANTI-NECTIN-4 ANTIBODY, DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SAOUD, CHRISTINE J | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685971 | ANTI-NECTIN-4 ANTIBODY, DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SAOUD, CHRISTINE J | 1645 | §112DP | Non-Final OA | — | Pending | Feb 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCspc Megalith Biopharmarceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Christine J Saoud has the most, with 1 of Cspc Megalith Biopharmarceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.